NASDAQ: MEDSTrxade Health Inc Stock
$6.26-0.19 (-2.95%)
Updated Apr 25, 2024
MEDS Price
$6.26
Fair Value Price
N/A
Market Cap
$8.80M
52 Week Low
$3.69
52 Week High
$44.56
P/E
-0.27x
P/B
16.23x
P/S
0.48x
PEG
N/A
Dividend Yield
127.8%
Revenue
$8.27M
Earnings
-$17.84M
Gross Margin
31.4%
Operating Margin
-201.22%
Profit Margin
-215.7%
Debt to Equity
22.11
Operating Cash Flow
-$2M
Beta
0.53
Next Earnings
Jun 14, 2024
Ex-Dividend
N/A
Next Dividend
N/A
MEDS Overview
TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O' Lakes, Florida.
Zen Score
–
Industry Average (19)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MEDS scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MEDS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MEDS is poor value based on its book value relative to its share price (16.23x), compared to the US Pharmaceutical Retailers industry average (1.14x)
P/B vs Industry Valuation
MEDS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 35 more MEDS due diligence checks available for Premium users.
Be the first to know about important MEDS news, forecast changes, insider trades & much more!
MEDS News
Valuation
MEDS fair value
Fair Value of MEDS stock based on Discounted Cash Flow (DCF)
Price
$6.26
Fair Value
-$5.10
Undervalued by
222.84%
MEDS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MEDS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.27x
Industry
-2.67x
Market
40.97x
MEDS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
16.23x
Industry
1.14x
MEDS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MEDS's financial health
Profit margin
Revenue
$2.4M
Net Income
-$11.7M
Profit Margin
-498%
MEDS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
MEDS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$12.5M
Liabilities
$12.0M
Debt to equity
22.11
MEDS's short-term liabilities ($11.56M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MEDS's short-term assets ($2.75M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MEDS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MEDS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$867.5k
Investing
-$350.0k
Financing
$1.3M
MEDS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MEDS vs Pharmaceutical Retailer Stocks
Trxade Health Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.